Avenue Therapeutics (FRA:49Y) EBIT per Share : €-12.03 (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Avenue Therapeutics EBIT per Share?

Avenue Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was €-0.93. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €-12.03.

During the past 3 years, the average EBIT per Share Growth Rate was 67.30% per year. During the past 5 years, the average EBIT per Share Growth Rate was 58.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Avenue Therapeutics's EBIT per Share or its related term are showing as below:

FRA:49Y' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -84.8 Med: 45.2 Max: 67.3
Current: 67.3

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Avenue Therapeutics was 67.30% per year. The lowest was -84.80% per year. And the median was 45.20% per year.

FRA:49Y's 3-Year EBIT Growth Rate is ranked better than
96.69% of 1237 companies
in the Biotechnology industry
Industry Median: 7.6 vs FRA:49Y: 67.30

Avenue Therapeutics's EBIT for the three months ended in Dec. 2024 was €-1.49 Mil.

Avenue Therapeutics EBIT per Share Historical Data

The historical data trend for Avenue Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenue Therapeutics EBIT per Share Chart

Avenue Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-285.67

-220.13

-79.52

-66.05

-32.76

Avenue Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															1.66	-7.12	-2.24	-1.74	-0.93

Avenue Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Avenue Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.17	/	2.054
=	-5.44

Avenue Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.489	/	2.054
=	-0.72

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.03

Avenue Therapeutics (FRA:49Y) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Avenue Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Avenue Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Avenue Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (FRA:49Y) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ATXI:USA

Address

1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154

Website

https://www.avenuetx.com

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.

Avenue Therapeutics Headlines

No Headlines